|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
|---|---|
| Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| ClinicalTrials.gov Identifier: | NCT00695227 |
Purpose
The purpose of this project is to develop an accurate method to identify patients that suffer from acid reflux, but may not present with classic reflux symptoms (such as heart burn). Additionally, it is the purpose of this project to utilize the Unsedated Small-caliber Endoscopy (USE) to assess the prevalence of Barrett's esophagus in a population of patients with laryngopharyngeal reflux (LPR) symptoms and to define normal patterns of LPR. Laryngopharyngeal reflux (LPR) is when a small amount of stomach contents and acid are pushed up through the esophagus and may affect the vocal cords and upper respiratory tract.
It is suspected that patients with LPR symptoms may have a prevalence of Barrett's esophagus similar to that found in a population with typical reflux symptoms. We propose to systematically test this hypothesis using the USE.
This project is designed to improve the methods of identifying patients with a form of acid reflux that is often undetected, and thus untreated. If this project is successful then more patients with Barrett's esophagus will be identified; furthermore, screening and treatment for this pre-cancerous condition will be improved.
| Condition | Intervention | Phase |
|---|---|---|
|
Extra Esophageal Symptoms: Cough Throat Clearing Hoarseness Difficulty Swallowing |
Drug: Proton Pump Inhibitor |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Screening for Barrett's Esophagus in Otolaryngology Patients |
| Estimated Enrollment: | 500 |
| Study Start Date: | May 2004 |
| Estimated Study Completion Date: | November 2012 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
-
Exclusion Criteria:
Contacts and Locations| United States, Oregon | |
| Oregon Health & Science University | |
| Portland, Oregon, United States, 97239-3098 | |
| Principal Investigator: | Joshua Schindler, MD | Oregon Health and Science University |
More Information
| Responsible Party: | Joshua Schindler, Oregon Health & Science University |
| ClinicalTrials.gov Identifier: | NCT00695227 History of Changes |
| Other Study ID Numbers: | K23 DK66165 (completed), DK066165-02 |
| Study First Received: | June 6, 2008 |
| Last Updated: | May 2, 2011 |
| Health Authority: | United States: Food and Drug Administration; United States: Federal Government |
|
laryngopharyngeal reflux extraesophageal reflux symptoms |
|
Barrett Esophagus Deglutition Disorders Esophageal Diseases Hoarseness Digestive System Abnormalities Digestive System Diseases Gastrointestinal Diseases Pharyngeal Diseases Otorhinolaryngologic Diseases Voice Disorders Laryngeal Diseases |
Respiratory Tract Diseases Respiration Disorders Neurologic Manifestations Nervous System Diseases Signs and Symptoms Signs and Symptoms, Respiratory Proton Pump Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |